Condition: Melanoma of Unknown Primary · Recurrent Melanoma · Stage IIIB Cutaneous Melanoma AJCC v7 · Sponsor: National Cancer Institute (NCI)
This randomized phase III trial studies ipilimumab to see how well it works compared to high-dose interferon alfa-2b in treating patients with high-risk stage III-IV melanoma that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma and other cancers. It is not yet known whether ipilimumab is more effective than interferon alfa-2b in treating patients with melanoma.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | — |
| Providence Hospital | Mobile, Alabama, United States | — |
| University of South Alabama Mitchell Cancer Institute | Mobile, Alabama, United States | — |
| Alaska Regional Hospital | Anchorage, Alaska, United States | — |
| Providence Alaska Medical Center | Anchorage, Alaska, United States | — |
| Fairbanks Memorial Hospital | Fairbanks, Alaska, United States | — |
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | — |
| University of Arizona Cancer Center-Orange Grove Campus | Tucson, Arizona, United States | — |
| Banner University Medical Center - Tucson | Tucson, Arizona, United States | — |
| University of Arizona Cancer Center-North Campus | Tucson, Arizona, United States | — |
| Mercy Hospital Fort Smith | Fort Smith, Arkansas, United States | — |
| NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro | Jonesboro, Arkansas, United States | — |
+ 926 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.